Department of Pathology, Kayseri City Hospital, Turkey.
Indian J Pathol Microbiol. 2021 Oct-Dec;64(4):671-676. doi: 10.4103/IJPM.IJPM_606_20.
We aimed to determine the hormone receptor status in breast cancers and to investigate the relationship between single hormone receptor-positive, double hormone receptor-positive, double hormone receptor negativity, and human epidermal growth factor receptor 2 (HER2) status and some clinicopathological features.
The study includes 85 patients who were diagnosed in our center between 2018 and 2019 and having surgical specimens were included in the study. Data of the cases, such as estrogen receptor (ER), progesterone receptor (PR), HER2 status, silver in situ hybridization (SISH) evaluation results, age distribution, histopathological findings were recorded.
We investigated the relationship between age, grade, tumor size, lymph node metastases and ER, PR, and HER2. However, there was not a significant association between ER, PR, and HER2 and age, tumor size, lymph node metastases (P > 0.05). On the other hand, we found a significant association between grades and ER (P = 0.02) and PR (P = 0.004), but not between grades and HER2 (P > 0.05). High-grade tumors were tumors with the lowest ER, PR positivity rate. Considering the four subtypes, cases aged above 45 years were at most double hormone receptor-positive (75%) and ER-positive/PR-negative (56%), respectively (P < 0.001). High-grade tumors were mostly double hormone receptor-negative and at least double hormone receptor positive. The ER-positive/PR-negative subtype was between these two groups (P < 0.001). The increased tumor size (T3) and increased metastatic lymph node number (N2 and N3) were observed at least in the ER-positive/PR-negative subtype. The majority of cases are in the older age group and invasive ductal carcinoma (IDC) is the most common tumor type. Older cases are most frequently double hormone receptor-positive and ER-positive/PR-negative, respectively. The ER, PR positivity rate is low in high-grade tumors. ER-positive/PR-negative tumors are of a higher grade than double hormone receptor-positive tumors, but they are of a lower grade than double hormone receptor-negative tumors. The increased tumor size and increased lymph node metastasis number are at most in the double hormone negative subtype and at least in the ER-positive/PR-negative subtype. The ER-negative/PR-positive subtype is observed very rarely, which raises the question of whether ER-negative/PR-positive tumors really exist. Further studies are needed to investigate this subtype and its properties.
本研究旨在确定乳腺癌中激素受体的状态，并探讨单激素受体阳性、双激素受体阳性、双激素受体阴性和人表皮生长因子受体 2（HER2）状态与某些临床病理特征之间的关系。
本研究纳入了 2018 年至 2019 年在我院诊断并接受手术标本的 85 例患者。记录了病例的雌激素受体（ER）、孕激素受体（PR）、HER2 状态、银原位杂交（SISH）评估结果、年龄分布、组织病理学发现等数据。
我们研究了年龄、分级、肿瘤大小、淋巴结转移与 ER、PR 和 HER2 之间的关系。然而，ER、PR 和 HER2 与年龄、肿瘤大小、淋巴结转移之间没有显著的相关性（P>0.05）。另一方面，我们发现分级与 ER（P=0.02）和 PR（P=0.004）之间存在显著相关性，而与 HER2 之间没有相关性（P>0.05）。高分级肿瘤的 ER、PR 阳性率最低。考虑到四个亚型，年龄在 45 岁以上的病例中，双激素受体阳性（75%）和 ER 阳性/PR 阴性（56%）最为常见（P<0.001）。高分级肿瘤大多为双激素受体阴性，至少为双激素受体阳性。ER 阳性/PR 阴性亚型处于这两组之间（P<0.001）。增加的肿瘤大小（T3）和增加的转移性淋巴结数量（N2 和 N3）至少在 ER 阳性/PR 阴性亚型中观察到。大多数病例处于老年组，最常见的肿瘤类型是浸润性导管癌（IDC）。年龄较大的病例分别以双激素受体阳性和 ER 阳性/PR 阴性为主。高分级肿瘤的 ER、PR 阳性率较低。ER 阳性/PR 阴性肿瘤的分级高于双激素受体阳性肿瘤，低于双激素受体阴性肿瘤。增加的肿瘤大小和增加的淋巴结转移数量在双激素受体阴性亚型中最多，在 ER 阳性/PR 阴性亚型中至少。ER 阴性/PR 阳性亚型非常罕见，这引发了一个问题，即 ER 阴性/PR 阳性肿瘤是否真的存在。需要进一步的研究来探讨这一亚型及其特性。
